Andere Sprachen Kymera Therapeutics, Inc.

Aktien

A2QBSH

US5015751044

KYMR

Realtime-Estimate Cboe BZX Andere Börsenplätze 15:42:41 25.04.2024			% 5 Tage	% 1. Jan.
33.49 ^USD	-4.88%		+4.30%	+38.30%

23.04.	KYMERA THERAPEUTICS, INC. : Oppenheimer bleibt bei seiner Kaufempfehlung	ZM
08.04.	Kymera Therapeutics, Inc. kündigt wissenschaftliche Präsentationen auf der Jahrestagung 2024 der American Association for Cancer Research an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2	13:00
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting	08.04.
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting	08.04.
Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting	08.04.
Kymera Therapeutics, Inc. Appoints Felix J. Baker to the Board	01.04.
Kymera Therapeutics Insider Sold Shares Worth $14,912,376, According to a Recent SEC Filing	14.03.
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting	11.03.
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting	08.03.
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting	08.03.
Kymera Therapeutics to Participate in Upcoming March Investor Conferences	28.02.
Kymera Therapeutics to Participate in Upcoming March Investor Conferences	28.02.
Kymera Therapeutics Q4 Net Loss Narrows, Collaboration Revenue Rises	22.02.
Kymera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.02.
Kymera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22.02.
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	22.02.
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	22.02.
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22	15.02.
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference	31.01.
Kymera Therapeutics Insider Sold Shares Worth $300,470, According to a Recent SEC Filing	24.01.
Kymera Therapeutics Raises $316.2 Million From Offering, Outlines Cash Runway Guidance	09.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Kymera Therapeutics, Inc.

Aktien

A2QBSH

US5015751044

KYMR

Andere Sprachen

Filter